Abstract:Importance: Clinical research has shown that persistent negative beliefs maintain depression and that subanesthetic ketamine infusions induce rapid antidepressant responses. Objective: To evaluate whether ketamine alters belief updating and how such cognitive effects are associated with the clinical effects of ketamine. Design, setting, and participants: This study used an observational case-control protocol with a mixed-effects design that nested 2 groups by 2 testing time points. Observers were not blinded. Patients with treatment-resistant depression (TRD) and healthy volunteer participants aged 34 to 68 years were included. Patients with TRD were diagnosed with major depressive disorder or bipolar depression, had a Montgomery-Åsberg Depression Rating Scale score greater than 20, a Maudsley Staging Method score greater than 7, and failed to respond to at least 2 prior antidepressant trials. Exclusion criteria were any other psychiatric, neurological, or neurosurgical comorbidities, substance use or addictive disorders, and recreational ketamine consumption. Data were collected from January to February 2019 and from May to December 2019, and data were analyzed from January 2020 to July 2021. Exposures: Patients with TRD were observed 24 hours before single ketamine infusion, 4 hours after the infusion, and 4 hours after the third infusion, which was 1 week after the first infusion. Healthy control participants were observed twice 1 week apart without ketamine exposure. Main outcomes and measures: Montgomery-Åsberg Depression Rating Scale score and belief updating after belief updating when patients received good news and bad news measured by a cognitive belief-updating task and mathematically formalized by a computational reinforcement learning model. Results: Of 56 included participants, 29 (52%) were male, and the mean (SEM) age was 52.3 (1.2) years. A total of 26 patients with TRD and 30 control participants were included. A significant group × testing time point × news valence interaction showed that patients with TRD updated their beliefs more after good than bad news following a single ketamine infusion (controlled for age and education: β = -0.91; 95% CI, -1.58 to -0.24; t216 = -2.67; P = .008) than controls. Computational modeling showed that this effect was associated with asymmetrical learning rates (LRs) after ketamine treatment (good news LRs after ketamine, 0.51 [SEM, 0.04]; bad news LRs after ketamine 0.36 [SEM, 0.03], t25 = 3.8; P < .001) and partially mediated early antidepressant responses (path a*b: β = -1.00 [SEM, 0.66]; t26 = -1.53; z = -1.98; P = .04). Conclusions and relevance: These findings provide novel insights into the cognitive mechanisms of the action of ketamine in patients with TRD, with promising perspectives for augmented psychotherapy for individuals with mood disorders.

Long-term outcomes of repeated ketamine infusions in patients with unipolar and bipolar depression: A naturalistic follow-up study.

Long-term quality of life after repeated ketamine infusions in anxious and nonanxious patients with depression

Non-improvement predicts subsequent non-response to repeated-dose intravenous ketamine for depression: a re-analysis of a 2-week open-label study in patients with unipolar and bipolar depression

Investigation of Medical Effect of Multiple Ketamine Infusions on Patients with Major Depressive Disorder

Long-term follow-up of participants in ketamine clinical trials for mood disorders

Can Quetiapine Prolong the Antidepressant Effect of Ketamine?: A 5-Year Follow-up Study

Residual Depressive Symptoms in Treatment-Resistant Bipolar Depression Following Short-Term Ketamine Administration

Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting

Baseline insomnia as a predictor of antidepressant efficacy to repeated intravenous ketamine for unipolar and bipolar depression: A preliminary study

Ketamine in multiple treatment-resistant depressed inpatients: A naturalistic cohort study

A Preliminary Study of Anti-Suicidal Efficacy of Repeated Ketamine Infusions in Depression with Suicidal Ideation

Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability

A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation

Suicidal ideation following ketamine prescription in patients with recurrent major depressive disorder: a nation-wide cohort study

Evaluation of Early Ketamine Effects on Belief-Updating Biases in Patients With Treatment-Resistant Depression

Association Between Depression Subtypes and Response to Repeated-Dose Intravenous Ketamine

Cognitive outcomes from the randomised, active-controlled Ketamine for Adult Depression Study (KADS)

IV low dose ketamine infusions for treatment resistant depression: Results from a five-year study at a free public clinic in an academic hospital

Change in Negative Affective Bias following a Single Ketamine Treatment for Treatment-Resistant Depression

Ketamine Exerts Its Sustained Antidepressant Effects Via Cell-Type-specific Regulation of Kcnq2.

Alterations of multiple peripheral inflammatory cytokine levels after repeated ketamine infusions in major depressive disorder